Utilisation des substances psychédéliques en thérapeutique et « auto-expérimentation » Docteur Christian SUEUR Colloque ATHS, 4 octobre 2019, Biarritz Le 14 mai dernier, est paru sur le site Vice.com, un article signé de Shayla Love, intitulé « The Ethics of Taking the Drugs You Study. Should psychedelic scientists trip on the drugs they research ? ».[1] Cette question pause la question, tant éthique que technique, de la nécessaire juxtaposition, lorsque l’on envisage la mise en place de thérapies psychédéliques, des apports récents de la neurobiologie éclairant le mode d’action cérébral des substances psychédéliques, et de la connaissance des effets psychiques de ces substances, grâce à l’auto-expérimentation des effets de [...]
Lire la suiteEntheogens — Sacramentals or Sacrilege ? (a working draft for a syllabus) Thomas ROBERTS in "Roberts, B. Thomas. (editor) (2012). Spiritual Growth with Entheogens" To most people who are even moderately experienced with entheogens, concepts such as awe, sacredness, eternity, grace, agapé, transcendence, transfiguration, dark night of the soul, born-again, heaven, and hell are more than theological ideas; they are experiences. Introduction to Entheogens: Sacramentals or Sacrilege? It should not be necessary to supply more proof that psychedelic drugs produce experiences that those who undergo them regard as religious in the fullest sense. Grinspoon and Bakalar, Psychedelic Drugs Reconsidered Are we experiencing a reorganization in Western religions now, [...]
Lire la suiteReview of Sacred Knowledge : Psychedelics and Religious Experience William A. Richards New York, NY: Columbia University Press, 2016. 269 pp. ISBN 978-0-231-17406-0 $29.95 Reviewed by Michael J. Winkelman http://dx.doi.org/10.1037/a0040299 Abstract Reviews the book, Sacred knowledge: Psychedelics and religious experiences, by William A. Richards. Richards’s career of clinical research with psychedelics and professional formation in theology, comparative religion and the psychology of religion bring integrative perspectives to understanding psychedelic experiences. Clinical accounts, scientific research and his personal experiences with psychedelics enable Richards to address issues of core importance in religious studies, medicine and society in general. Clinical studies with psychedelics provide findings that contribute to assessment of [...]
Lire la suiteScientists mass-produce 'magic mushroom' active ingredient from bacteria The study shows that psilocybin can be produced in a sustainable manner. https://www.zmescience.com/medicine/scientists-mass-produce-magic-mushroom-active-ingredient-from-bacteria/ byTibi Puiu October 3, 2019 Psilocybin, the active psychoactive compound found in specific mushrooms, is a promising drug that can be used to treat depression, anxiety, addiction, and post-traumatic stress disorder. Looking towards the future, researchers at Miami University have used genetic engineering to coax harmless E. coli bacteria to produce psilocybin. Psilocybe semilanceata. Credit: Pixabay. The mushrooms that produce psilocybin, such as Psilocybe cubensis, are not particularly expensive or difficult to grow. However, they do take up a lot of space and require many [...]
Lire la suiteAyahuasca, Psychedelic Studies and Health Sciences: The Politics of Knowledge and Inquiry into an Amazonian Plant Brew Kenneth W. Tupper, and Beatriz C. Labate Current Drug Abuse Reviews, 2014, 7, 71-80 Abstract : This article offers critical sociological and philosophical reflections on ayahuasca and other psychedelics as objects of research in medicine, health and human sciences. It situates 21st century scientific inquiry on ayahuasca in the broader context of how early modern European social trends and intellectual pursuits translated into new forms of empiricism and experimental philosophy, but later evolved into a form of dogmatism that convenienced the political suppression of academic inquiry into [...]
Lire la suiteOf Roots and Fruits : A Comparison of Psychedelic and Non-psychedelic Mystical Experiences David B. Yaden, Khoa D. Le Nguyen, Margaret L. Kern, Alexander B. Belser, Johannes C. Eichstaedt, Jonathan Iwry, Mary E. Smith, Nancy A. Wintering, Ralph W. Hood Jr., and Andrew B. Newberg Journal of Humanistic Psychology, 2017, Vol. 57, (4), 338–353 DOI: 10.1177/0022167816674625 Abstract Experiences of profound existential or spiritual significance can be triggered reliably through psycho-pharmacological means using psychedelic substances. However, little is known about the benefits of religious, spiritual, or mystical experiences (RSMEs) prompted by psychedelic substances, as compared with those that occur through other means. In this study, 739 self-selected [...]
Lire la suiteThe endocannabinoid system : an overview Natalia Battista, Monia Di Tommaso, Monica Bari and Mauro Maccarrone Frontiers in Behavioral Neuroscience, 2012|Volume 6|Article 9 | 1 doi: 10.3389/fnbeh.2012.00009 Upon the identification of anandamide (AEA) in the porcine brain, numerous studies contributed to the current state of knowledge regarding all elements that form the “endocannabinoidsystem (ECS).” How this complex system of receptors, ligands, and enzymes is integrated in helping to regulate fundamental processes at level of central nervous and peripheral systems and how its regulation and dysregulation might counteract disturbances of such functions, is now a days still under investigation. However, the most recent advances on [...]
Lire la suiteCannabinoids, Endocannabinoids and Cancer Daniel J. Hermanson and Lawrence J. Marnett Cancer Metastasis Reviews, 2011, 30, (3-4), 599–612. doi:10.1007/s10555-011-9318-8. 1. Introduction 1.1 Cannabinoid Function Endocannabinoids are bioactive lipids that have a range of interesting activities mediated by two G-protein-coupled receptors (CB1 and CB2) and other putative targets [1-3]. The CB1 receptor is present in the central nervous system and mediates the psychotropic effects of exogenous cannabinoids such as Δ9-tetrahydrocannabinol (THC), the active component of marijuana. In the brain, endocannabinoids and cannabinoids combine with CB1 cannabinoid receptors on axon terminals and regulate ion channel activity and neurotransmitter release [4]. Binding to the CB1 receptor is responsible for [...]
Lire la suiteOpportunities for cannabis in supportive care in cancer Amber S. Kleckner , Ian R. Kleckner, Charles S. Kamen, Mohamedtaki A. Tejani, Michelle C. Janelsins, Gary R. Morrow and Luke J. Peppone Therapeutic Advances in Medical Oncology, 2019, Vol. 11, 1–29 Doi : 10.1177/1758835919866362 Abstract Cannabis has the potential to modulate some of the most common and debilitating symptoms of cancer and its treatments, including nausea and vomiting, loss of appetite, and pain. However, the dearth of scientific evidence for the effectiveness of cannabis in treating these symptoms in patients with cancer poses a challenge to clinicians in discussing this option with their patients. A review [...]
Lire la suiteLegal highs : staying on top of the flood of novel psychoactive substances David Baumeister, Luis M. Tojo and Derek K. Tracy Therapeutic Advances in Psychopharmacology, 2015, Vol. 5, (2), 97–132 DOI: 10.1177/2045125314559539 Abstract : There has been growing clinical, public, and media awareness and concern about the availability and potential harmfulness of so-called ‘legal highs’, which are more appropriately called new or novel psychoactive substances (NPS). A cat-and-mouse process has emerged wherein unknown chemists and laboratories are producing new, and as yet nonproscribed, compounds for human consumption; and as soon as they are banned, which they inevitably are, slightly modified analogues are produced to [...]
Lire la suite